About pulse biosciences inc - PLSE
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.
PLSE At a Glance
Pulse Biosciences, Inc.
601 Brickell Key Drive
Miami, Florida 33131
| Phone | 1-510-906-4600 | Revenue | 350.00K | |
| Industry | Medical Specialties | Net Income | -72,781,000.00 | |
| Sector | Health Technology | Employees | 116 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PLSE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2,643.823 |
| Price to Book Ratio | 11.548 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -11.232 |
| Enterprise Value to Sales | 2,434.666 |
| Total Debt to Enterprise Value | 0.009 |
PLSE Efficiency
| Revenue/Employee | 3,017.241 |
| Income Per Employee | -627,422.414 |
| Receivables Turnover | 1.277 |
| Total Asset Turnover | 0.003 |
PLSE Liquidity
| Current Ratio | 10.529 |
| Quick Ratio | 10.512 |
| Cash Ratio | 10.19 |
PLSE Profitability
| Gross Margin | -360.00 |
| Operating Margin | -21,982.571 |
| Pretax Margin | -20,794.571 |
| Net Margin | -20,794.571 |
| Return on Assets | -63.241 |
| Return on Equity | -74.449 |
| Return on Total Capital | -82.531 |
| Return on Invested Capital | -69.64 |
PLSE Capital Structure
| Total Debt to Total Equity | 9.336 |
| Total Debt to Total Capital | 8.539 |
| Total Debt to Total Assets | 7.834 |
| Long-Term Debt to Equity | 7.389 |
| Long-Term Debt to Total Capital | 6.758 |